Research Article
Mesenchymal Stem Cells: A New Choice for Nonsurgical Treatment of OA? Results from a Bayesian Network Meta-Analysis
Table 1
The details of SURCA and mean rank of efficacy endpoints.
| | Treatment | SMD (95% CI) for pain relief | SURCA for pain relief (%) | Mean rank for pain relief | SMD (95% CI) for function improvement | SURCA for function improvement (%) | Mean rank for function improvement | SMD (95% CI) for stiffness improvement | SURCA for stiffness improvement (%) | Mean rank for stiffness improvement |
| | Placebo | Reference | 24.3 | 4.0 | Reference | 24.5 | 4.0 | Reference | 19.8 | 4.2 | | MSCs | 3.61 (1.87, 5.35) | 97.9 | 1.1 | 2.37 (0.81, 3.93) | 95.9 | 1.2 | 1.02 (0.11, 1.94) | 87.6 | 1.5 | | PRP | 1.31 (0.13, 2.50) | 71.8 | 2.1 | 1.40 (0.30, 2.49) | 75.9 | 2.0 | 0.89 (0.27, 1.51) | 84.1 | 1.6 | | HA | 0.83 (0.08, 1.58) | 54.5 | 2.8 | 0.81 (0.09, 1.52) | 52.7 | 2.9 | 0.34 (-0.09, 0.77) | 48.7 | 3.1 | | GCs | -1.25 (-2.67, 0.17) | 1.5 | 4.9 | -1.25 (-2.69, 0.20) | 1.1 | 5.0 | -0.21 (-0.98, 0.56) | 9.7 | 4.6 |
|
|
